Value of functional in-vivo endpoints in preclinical radiation research
Publikation: Beitrag in Fachzeitschrift › Forschungsartikel › Beigetragen › Begutachtung
Beitragende
Abstract
BACKGROUND: Cancer research faces the problem of high rates of clinical failure of new treatment approaches after positive preclinical data. We hypothesize that a major confounding factor to this problem in radiooncology is the choice of the preclinical endpoint.
METHODS: We present a comprehensive re-evaluation of large-scale preclinical in-vivo data on fractionated irradiation alone or simultaneously with Epidermal Growth Factor Receptor inhibition. Taking the permanent local tumour control assay as a gold standard, we evaluated different tumour volume dependent endpoints that are widely used for preclinical experiments.
RESULTS: The analysis showed the highest correlations between volume related and local tumour control endpoints after irradiation alone. For combined treatments, wide inter-tumoural variations were observed with reduced correlation between the endpoints. Evaluation of growth delay per Gray (GD/Gy) based on two or more dose levels showed closest correlation with local tumour control dose 50% (TCD50).
CONCLUSIONS: GD/Gy with at least two dose groups correlates with TCD50, but cannot replace the latter as the goldstandard.
Details
Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 155-161 |
Seitenumfang | 7 |
Fachzeitschrift | Radiotherapy and Oncology |
Jahrgang | 158 |
Publikationsstatus | Veröffentlicht - Mai 2021 |
Peer-Review-Status | Ja |
Externe IDs
Scopus | 85102337604 |
---|---|
ORCID | /0000-0002-7017-3738/work/142253937 |
ORCID | /0000-0003-1776-9556/work/171065686 |
Schlagworte
Ziele für nachhaltige Entwicklung
Schlagwörter
- Animals, Carcinoma, Squamous Cell, Combined Modality Therapy, Humans, Mice, Mice, Nude, Transplantation, Heterologous